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ABSTRACT 
 
Objective: Cervical cancer is the second common type of cancer among women in the Indonesian 
population. Persistent infection with high risk Human papillomavirus (hrHPV) has been considered 
as the most significant risk factor of cervical cancer. Research on the identification of HPV type 45 
L2 gene as the third cause of cervical cancer in Indonesia is still small even has not been done in West 
Sumatera and Riau, whereas HPV gene identification by molecular biology techniques can be used 
as an initial screening for cervical cancer.  
 
Methods: DNA was isolated from 43 samples of cervical smears and cervical cancer biopsies 
obtained from M. Djamil General Hospital Padang and Arifin Achmad General Hospital Pekanbaru. 
HPV DNA detection was conducted using polymerase chain reaction (PCR) using GP5+/6+ primers. 
HPV type 45 L2 gene was identified by PCR method with HPV type 45 L2 gene specific primers. 
 
Results: The concentration of the isolated DNA varied from 2.8 to 326.3 ng/µl. Isolates DNA from 
tissue samples had good value of purity and the purity of isolated DNA from cervical smears samples 
was not too good. Amplification of HPV DNA showed that 20 tissue samples and 6 cervical smear 
samples were positive HPV DNA. There was only one sample (Hpv.J.14) which L2 genes of HPV 
type 45. 
Conclusion: Results of DNA amplification by PCR method showed that 60.47% of cervical cancer 
patients in this study infected with HPV DNA and 3.85% sample had gene L2 of HPV type 45.  
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INTRODUCTION 
Cervical cancer is the fourth most common cancer in the world. The second most cancer incidence in 
Indonesian women is cervical cancer [1]. Infection of high risk Human papillomavirus (HPV) known 
as the main factor that causes cervical cancer.  
International Agency for Research on Cancer (IARC) of the 1000 samples from 22 countries found 
the 99.7% of the cervical cancer's presence of HPV infections [2]. HPV contributes to the 
development of cancer by their E6 and E7 genes. Based on their oncogenicity against cervical cancer, 
HPV can be divided into high risk HPV and low risk HPV [3].  
 
HPV type 45 as high risk HPV was first discovered in 1987. Based on Guan (2012) research from 
115.789 positive samples of HPV, HPV type 45 is the third cause after HPV type 16 and HPV type 
18 [4]. In Indonesia, prevalence HPV type 45 in cervical cancer is 13.7% and it noted as the third 
HPV cause cervical cancer [1]. Identification of  HPV genes with specific and sensitive molecular 
biology techniques, such as polymerase chain reaction (PCR) can be used as an initial screening for 
cervical cancer [5].  
In Indonesia, the identification of HPV genes focused on HPV types 16 and 18. Meanwhile, research 
on the identification of genes of HPV type 45 is still  small even have not been done in  West Sumatera 
and Riau. The aim this study was to detect the  L2 genes of HPV types 45 from cervical cancer 
patients in west Sumatera and Riau used PCR method. 
 
MATERIALS AND METHODS 
 
Sample collection 
A total of 43 samples used in this study. Formalin-fixed paraffin-embedded samples of cervical cancer 
biopsy (4 samples), fresh tissue samples cervical cancer biopsy (20 samples) was collected from Dr 
M. Djamil general  hospital in Padang, West Sumatera. Cervical smear samples (19 samples) from 
cervical cancer patients  Arifin Achmad general hospital in Pekanbaru, Riau also used in this study. 
The samples were taken from patients who were treated during the period of April- July 2015. 
Consent of the patient for the use of their samples for research purpose was taken. 
 
Isolation of Human papillomavirus DNA 
The tissue samples were isolated using DNA Extraction Kit gSYNCTM and cervical smear samples 
were isolated using Genomic DNA Mini LinkTM Pure Kit (InvitrogenTM). Isolation of DNA was done 
according to the protocol of the kit being used. 
 
Concentration and purity of DNA isolated 
Quantification was made using a Nanodrop spectrophotometer at 260 and 280 nm. DNA purity is 
determined based on the value ratio A260 / 280 with units of ng/µl. First the optical hole cleaned with 
a tissue. Nuclease free water was used as blank. 1 ml nuclease free water put in into the optical hole. 
Then, the optical hole was cleaned again before the sample is introduced. A total of 2 ml of sample 
DNA is inserted into optical hole. Absorbance value measured at 260 and 280 nm. 
 
Detection of HPV DNA   
HPV DNA detection had done by using HPV GP5+/6 +  primer (forward 5'-TTT GTT GTA GTG 
GAT ACT ACT AC-3'dan reverse 5'-GAA AAA TAA ACT CAT AAT GTA ATT C-3 ') with product 
length 150 bp [6]. Prepared 25 µl of the PCR mix solution, consist of  1.5 µl DNA template, 0.5 µl 
primer Foward, 0.5 µl Reverse Primer, and 22.5 µl Platinium® PCR Super Mix. The PCR conditions 
were hot start 94 0C (5 min), denaturation 94 0C (30 s), annealing 50 0C (60 s), extension 72 0C (60 
s) and final extension 72 0C (10 min). The amplified products were analyzed on a 1.5% agarose gel, 
stained with SYBR Safe and visualized in gel documentation system. 
 
Detection of HPV type 45 L2 gene 
The identification had done by using specific primer of HPV types 45 L2 gene with product length 
298 bp. Prepared 25 µl of the PCR mix solution, consist of  1.5 µl DNA template, 0.5 µl primer 
Foward (TAC ACC CAC CAT GGA CGT GGA C), 0.5 µl Reverse Primer (CTG ACG CAC TGA 
GGA GAC GGT C), and 22.5 µl Platinium® PCR Super Mix. The PCR conditions were hot start 94 
0C (5 min), denaturation 95 0C (30 s), annealing 59 0C (30 s), extension 72 0C (60 s) and final 
extension 72 0C (10 min). The amplified products were analyzed on a 1.5% agarose gel, stained with 
SYBR Safe and visualized in gel documentation system. 
 
RESULT AND DISCUSSION 
 
The concentration of isolated DNA 
The concentration of the isolated DNA varied from 2.8 to 326.3 ng/µl. The DNA concentration of 
10-100 mg per µl solution is the best template for PCR but the most important is the DNA must be 
free of impurities such as proteins, phenol, and alcohol [7]. Most of isolated DNA from tissue samples 
had DNA concentration more than 10 ng/ml. Only samples Hpv.J.9, Hpv.J.12, and Hpv.J.16, which 
has a DNA concentration of less than 10 ng/µl (Table 1).  
 
Table 1: Concentration and purity of isolated DNA from tissue samples 
Sample Concentration 
(ng/µl) 
A260  A280 Purity 
(A260/A280) 
Hpv.J.1 19.2 0.384 0.205 1.87 
Hpv.J.2 18.7 0.374 0.188 1.99 
Hpv.J.3 18.5 0.371 0.182 2.04 
Hpv.J.4 104.3 2.086 1.033 2.02 
Hpv.J.5 48.3 0.966 0.468 2.06 
Hpv.J.6 18.9 0.379 0.174 2.18 
Hpv.J.7 31.5 0.629 0.305 2.06 
Hpv.J.8 102.7 2.054 1.023 2.01 
Hpv.J.9 6.9 0.138 0.064 2.16 
Hpv.J.10 40.4 0.808 0.368 2.20 
Hpv.J.11 160 3.201 1.672 1.91 
Hpv.J.12 7.6 0.152 0.066 2.30 
Hpv.J.13 282.9 5.659 2.954 1.92 
Hpv.J.14 17.5 0.350 0.193 1.81 
Hpv.J.15 22.4 0.448 0.206 2.17 
Hpv.J.16 8.8 0.177 0.084 2.11 
Hpv.J.17 172.5 3.450 1.792 1.93 
Hpv.J.18 326.3 6.525 3.427 1.90 
Hpv.J.19 217.9 4.357 2.301 1.89 
Hpv.J.20 167.3 3.345 1.745 1.92 
Hpv.J.21 31.7 0.634 0.329 1.93 
Hpv.J.22 49.9 0.999 0.511 1.95 
Hpv.J.23 65.9 1.318 0.706 1.87 
Hpv.J.24 12.6 0.253 0.125 2.02 
A260: Absorbance on 260 nm wavelengths 
A280: Absorbance on 280 nm wavelengths 
 
On 19 cervical smear samples, only samples Hpv.A.18, Hpv.A.7, Hpv.A.1 had good concentration ≥ 10 
ng/µl (Table 2). DNA concentrations less than 10 ng/µl can reduce the efficiency of DNA 
amplification using PCR methods [7]. DNA isolated from cervical smear had a smaller concentration 
of DNA compared to DNA derived from the tissue sample. 
 
Table 2: Concentration and purity of isolated DNA from cervical smear samples 
Sample Concentration 
(ng/µl) 
A260  A280 Purity 
(A260/A280) 
Hpv.A.1 11.6 0.231 0.120 1.93 
Hpv.A.2 7.7 0.153 0.069 2.22 
Hpv.A.3 6.3 0.125 0.062 2.02 
Hpv.A.4 4.2 0.083 0.035 2.37 
Hpv.A.5 7.3 0.146 0.068 2.15 
Hpv.A.6 3.1 0.061 0.024 2.54 
Hpv.A.7 10.0 0.200 0.109 1.83 
Hpv.A.8 3.4 0.069 0.049 1.41 
Hpv.A.9 3.5 0.070 0.049 1.43 
Hpv.A.10 2.8 0.056 0.053 1.06 
Hpv.A.11 3.0 0.061 0.046 1.33 
Hpv.A.12 3.5 0.069 0.041 1.68 
Hpv.A.13 7.1 0.142 0.089 1.60 
Hpv.A.14 6.5 0.130 0.080 1.63 
Hpv.A.15 6.3 0.126 0.074 1.70 
Hpv.A.16 4.5 0.090 0.052 1.73 
Hpv.A.17 3.9 0.079 0.047 1.68 
Hpv.A.18 16.5 0.330 0.187 1.76 
Hpv.A.19 4.5 0.091 0.059 1.54 
                  A260: Absorbance on 260 nm wavelengths 
      A280: Absorbance on 280 nm wavelengths 
 
The purity of isolated DNA  
The Purity of isolated DNA also could affect DNA amplification by PCR. DNA contamination can 
cause errors such as the unwanted and non-specific amplification products [7]. DNA purity 
determined by comparing the absorbance value at 260 nm wavelengths and 280 nm wavelengths. In 
molecular analysis, DNA is pure if A260/A280 ranged from 1.8 to 2.0. The  Purity <1.8 means that 
there are still a protein contamination or reagents used in the process of DNA isolation [8]. 
 
Isolates DNA from tissue samples had good value of purity. Purity of isolated DNA from tissue 
samples Hpv.J.3, Hpv.J.4, Hpv.J.5, Hpv.J.6, Hpv.J.7, Hpv.J.8, Hpv.J.9, Hpv.J.10, Hpv.J.12, Hpv.J.15, Hpv.J.16 
and Hpv.J.24 was > 2.0 (Table 1). But the great value of purity that this will not affect the results of 
DNA amplification because the value of purity 2.0 does not indicate any fault in the process of 
isolation [8]. The purity of isolated DNA of cervical smear samples was not good, because only a 
sample Hpv.A.7 and Hpv.A.1 that meet the range of purity for molecular analysis (Table 2). Low DNA 
purity grades can be caused by proteins and other contaminants in the isolated DNA.  
 
 
Detection of HPV DNA  
Results of DNA amplification using PCR method for the detection of HPV DNA shown 26 of the 43 
samples in this study had HPV DNA. In the gel photograph the results of DNA amplification using 
GP5+/6+ primer, samples Hpv.J.2, Hpv.J.3, Hpv.J.4, Hpv.J.5, Hpv.J.6, Hpv.J.7, Hpv.J.8, Hpv.J.9, Hpv.J.10, 
Hpv.J.11,  Hpv.J.13, Hpv.J.14, Hpv.J.15, Hpv.J.16, Hpv.J.17, Hpv.J.18, Hpv.J.19, Hpv.J.22, Hpv.J.23, Hpv.J.24,  
Hpv.A.2, Hpv.A.3, Hpv.A.4, Hpv.A.5, Hpv.A.6, Hpv.A.7  appear on the band at 150 bp, shown in (Fig. 1-
5). This indicates that the sample is positive for HPV DNA.  
 
Fig 1: Detection of DNA HPV on  Hpv.J.1 - Hpv.J.12 Samples 
L: DNA Ladder, 1: Hpv.J.1, 2: Hpv.J.2,3: Hpv.J.3 ,4 : Hpv.J.4, 5 : Hpv.J.5 , 6: Hpv.J.6, 7: Hpv.J.7, 8: 
Hpv.J.8, 9: Hpv.J.9, 10: Hpv.J.10, 11: Hpv.J.11, 12: Hpv.J.12 
 
 
Fig 2: Detection of DNA HPV on  Hpv.J.13 - Hpv.J.22 Samples 
L: DNA Ladder, 1: Hpv.J.13, 2: Hpv.J.14,3: Hpv.J.15  4 : Hpv.J.16, 5 : Hpv.J.17 , 6: Hpv.J.18, 7: 
Hpv.J.19, 8: Hpv.J.20, 9: Hpv.J.21, 10: Hpv.J.22 
 
From this study, note that 60.47% of cervical cancer patients in West Sumatera and Riau infected by 
Human papillomavirus. While the results of research by the International Agency for Research on 
Cancer (IARC) of the 1000 samples shown 99.7% of 22 HPV infection in cervical cancer patients 
[2]. This suggests that HPV infection in cervical cancer patients in West Sumatra and Riau has a 
smaller percentage than HPV infection in cervical cancer patients in the world. 
 
Fig 3: Detection of DNA HPV on  Hpv.J.23 - Hpv.J.24 Samples 
L: DNA Ladder, 1: Hpv.J.23, 2: Hpv.J.24 
 
The  difference in the prevalence of HPV in cervical cancer patients in West Sumatra and Riau within 
the world can be due to differences in the number of samples studied and because of cultural factors 
[9]. Cervical cancer suffered by patients in this study were not infected with HPV can be caused by 
other risk factors such as smoking causes cervical cancer, use of oral contraceptives, weak immune 
system and Chlamydia and HSV infection. These risk factors may not directly cause cervical cancer, 
but it happens gradually. 
 
Fig 4: Detection of DNA HPV on  Hpv.A.1 - Hpv.A.7 Samples 
L: DNA Ladder, 1: Hpv.A.1, 2: Hpv.A.2,3: Hpv.A.3 ,4 : Hpv.A.4, 5 : Hpv.A.5 , 6: Hpv.A.6, 7: Hpv.A.7 
 
Fig 5: Detection of DNA HPV on  Hpv.A.8 - Hpv.A.19 Samples 
L: DNA Ladder, 1: Hpv.A.8, 2: Hpv.A.9, 3: Hpv.A.10,4 : Hpv.A.11, 5 : Hpv.A.12 , 6: Hpv.A.13, 7: 
Hpv.A.14 , 8 : Hpv.A.15, 9: Hpv.A.16 , 10: Hpv.A.17, 11: Hpv.A.18 , 12: Hpv.A.19 
 
Detection of HPV type 45 L2 gene  
 
HPV types 45 consist of 7858 base pairs with 8 ORF is E1, E2, E4, E5, E6, E7 and L1 and L2. HPV 
types 45 L2 gene arranges by 1,392 base pairs that are at the base of 4,236 to 5,627 on the HPV type 
45. L2 gene serves as a minor constituent viral capsid. Structural studies indicate that the new L2 
genes are expressed in a complex stage of virus infection. So that these genes can only be identified 
in patients with cervical cancer. L2 gene identification is important as a first step to designing a 
prophylactic vaccine for HPV infection [10]. 
 
Identification of HPV type 45 L2 gene was performed using specific primers of HPV types 45 L2 
gene by PCR showing only positive samples containing genes Hpv.J.14 HPV L2 45 (Fig. 6) Where the 
band appeared on 298 bp. Other samples did not show band on the 298 bp, so it concluded that these 
samples did not have L2 genes of HPV type 45.  
 
 
Fig 6: Identification of HPV Type 45 L2 gene on  Hpv.J.13 - Hpv.J.22 Samples 
L: DNA Ladder, 1: Hpv.J.13, 2: Hpv.J.14,3: Hpv.J.15  4 : Hpv.J.16, 5 : Hpv.J.17 , 6: Hpv.J.18, 7: 
Hpv.J.19, 8: Hpv.J.20, 9: Hpv.J.21, 10: Hpv.J.22 
 
The prevalence of HPV 45 in this study, 3.85% (n: 1) of 26 samples were HPV positive. Compared 
to other regions in Indonesia such as Bandung 28.8% (n: 19) of 66 samples [11], Jakarta 3.3% (n: 4) 
of the 122 samples, Bali 6% (n: 6) of the 102 samples and Tasikmalaya 1.2% (n: 1) of 81 samples 
[12], the prevalence of HPV 45 in the region of West Sumatra and Riau are not too high. 
 
 
 
 
CONCLUSION 
 
DNA amplification by PCR method showed that 60.47% of cervical cancer patients in this study 
infected with HPV DNA and there is only one sample (Hpv.J.14) which L2 genes of HPV type 45. 
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